Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Xiao-Ji Lin, Li-Meng Cai, Zi-Jun Qian, Chen-Yi Wang, Ni Sun, Xiao-Hai Sun, He Huang, Wen-Jian Guo, Hai-Yan Lin & Rong-Xin Yao. (2017) Increased histone deacetylase 6 expression serves as a favorable prognostic factor for diffuse large B-cell lymphoma. OncoTargets and Therapy 10, pages 5129-5136.
Read now
Read now
Articles from other publishers (18)
Alessandro Allegra, Vanessa Innao, Francesca Polito, Rosaria Oteri, Angela Alibrandi, Andrea Gaetano Allegra, Giacomo Oteri, Rosa Maria Di Giorgio, Caterina Musolino & M'hammed Aguennouz. (2021) SIRT2 and SIRT3 expression correlates with redox imbalance and advanced clinical stage in patients with multiple myeloma. Clinical Biochemistry 93, pages 42-49.
Crossref
Crossref
Mussa Yussuf Khamis, Hui-Pan Wu, Qin Ma, Yi-Han Li, Li-Ying Ma, Xin-Hui Zhang & Hong-Min Liu. (2021) Overcome the tumor immunotherapy resistance by combination of the HDAC6 inhibitors with antitumor immunomodulatory agents. Bioorganic Chemistry 109, pages 104754.
Crossref
Crossref
Rosa María Tordera & María Cortés-Erice. 2021. Reviews of Physiology, Biochemistry and Pharmacology. Reviews of Physiology, Biochemistry and Pharmacology
1
47
.
Tobias S. Iveland, Lars Hagen, Animesh Sharma, Mirta M. L. Sousa, Antonio Sarno, Kristian Lied Wollen, Nina Beate Liabakk & Geir Slupphaug. (2020) HDACi mediate UNG2 depletion, dysregulated genomic uracil and altered expression of oncoproteins and tumor suppressors in B- and T-cell lines. Journal of Translational Medicine 18:1.
Crossref
Crossref
Ekta Shirbhate, Preeti Patel, Vijay K Patel, Ravichandran Veerasamy, Prabodh C Sharma & Harish Rajak. (2020) The combination of histone deacetylase inhibitors and radiotherapy: a promising novel approach for cancer treatment. Future Oncology 16:30, pages 2457-2469.
Crossref
Crossref
Hao Hu, Fei Chen, Yuhong Dong, Yajing Liu & Ping Gong. (2020) Discovery of novel dual c-Met/HDAC inhibitors as a promising strategy for cancer therapy. Bioorganic Chemistry 101, pages 103970.
Crossref
Crossref
Michael R. Stallcup & Coralie Poulard. (2020) Gene-Specific Actions of Transcriptional Coregulators Facilitate Physiological Plasticity: Evidence for a Physiological Coregulator Code. Trends in Biochemical Sciences 45:6, pages 497-510.
Crossref
Crossref
Ying Xie, Jing Liu, Hongmei Jiang, Jingya Wang, Xin Li, Jingjing Wang, Shuai Zhu, Jing Guo, Tao Li, Yuping Zhong, Qiguo Zhang & Zhiqiang Liu. (2019) Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma. Oncogene 39:4, pages 922-934.
Crossref
Crossref
Feifei Yang, Na Zhao, Di Ge & Yihua Chen. (2019) Next-generation of selective histone deacetylase inhibitors. RSC Advances 9:34, pages 19571-19583.
Crossref
Crossref
Ota Fuchs. (2019) Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs. Cardiovascular & Hematological Disorders-Drug Targets 19:1, pages 51-78.
Crossref
Crossref
Zhaoyun Liu, Qian Jing, Yangyang Wang, Yanqi Li, Fu Mi, Chenhuan Xiang & Rong Fu. (2018) The short-term effect of histone deacetylase�inhibitors, chidamide and valproic acid, on�the�NF‑κB�pathway in multiple myeloma cells. International Journal of Molecular Medicine.
Crossref
Crossref
Sara Gandolfi, Claudia Paba Prada & Paul G. Richardson. (2018) How I treat the young patient with multiple myeloma. Blood 132:11, pages 1114-1124.
Crossref
Crossref
Eleni-Dimitra Papanagnou, Evangelos Terpos, Efstathios Kastritis, Issidora S. Papassideri, Ourania E. Tsitsilonis, Meletios A. Dimopoulos & Ioannis P. Trougakos. (2018) Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent. Oncotarget 9:25, pages 17797-17809.
Crossref
Crossref
Lev Litichevskiy, Ryan Peckner, Jennifer G. Abelin, Jacob K. Asiedu, Amanda L. Creech, John F. Davis, Desiree Davison, Caitlin M. Dunning, Jarrett D. Egertson, Shawn Egri, Joshua Gould, Tak Ko, Sarah A. Johnson, David L. Lahr, Daniel Lam, Zihan Liu, Nicholas J. Lyons, Xiaodong Lu, Brendan X. MacLean, Alison E. Mungenast, Adam Officer, Ted E. Natoli, Malvina Papanastasiou, Jinal Patel, Vagisha Sharma, Courtney Toder, Andrew A. Tubelli, Jennie Z. Young, Steven A. Carr, Todd R. Golub, Aravind Subramanian, Michael J. MacCoss, Li-Huei Tsai & Jacob D. Jaffe. (2018) A Library of Phosphoproteomic and Chromatin Signatures for Characterizing Cellular Responses to Drug Perturbations. Cell Systems 6:4, pages 424-443.e7.
Crossref
Crossref
Ping-Pin Zheng, Jin Li & Johan M Kros. (2018) Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights. Medicinal Research Reviews 38:1, pages 325-376.
Crossref
Crossref
Gerald Davies, Liubov Lobanova, Wojciech Dawicki, Gary Groot, John R. Gordon, Matthew Bowen, Troy Harkness & Terra Arnason. (2017) Metformin inhibits the development, and promotes the resensitization, of treatment-resistant breast cancer. PLOS ONE 12:12, pages e0187191.
Crossref
Crossref
Alawi H. Habara, Elmutaz M. Shaikho & Martin H. Steinberg. (2017) Fetal hemoglobin in sickle cell anemia: The Arab-Indian haplotype and new therapeutic agents. American Journal of Hematology 92:11, pages 1233-1242.
Crossref
Crossref
Saurabh Chhabra. (2017) Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics. Pharmaceuticals 10:4, pages 40.
Crossref
Crossref